Drug intelligence / Profile preview

KQB162

Development stage: Unknown
Lead developer: Kumquat Biosciences
Modality: Small Molecules

Overview

KQB162 is an investigational drug candidate developed by Kumquat Biosciences targeting the RAS pathway. It is currently in the IND-enabling stage, which means it is undergoing preclinical development to support an Investigational New Drug (IND) application for entry into human clinical trials. The RAS pathway is a critical signaling cascade involved in cell growth and survival, and mutations in this pathway are commonly implicated in various cancers. By targeting the RAS pathway, KQB162 aims to provide a novel therapeutic approach for cancer treatment[1].

Targets

Mutant Kirsten rat sarcoma virus oncogene homolog (KRAS) neoantigen

Beyond the preview

Go deeper on KQB162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQB162.

Explore the full profile